Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: A single-centre experience

Internal Medicine Journal

Volumn 39, Issue 1, 2009, Pages 19-24

  Frawley, N ^a   Ng, A P ^a   Nicholls, K ^a   Cohney, S ^a   Hogan, C ^a   Grigg, A ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Neurological feature; Plasma exchange; Rituximab; Steroid; Thrombotic thrombocytopenic purpura

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTENSIVE CARE; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; SEPSIS; SURVIVAL; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 61849182090     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01637.x     Document Type: Article

References (21)

1. Terrell DR, Williams LA, Vesely SK, Lammle B, Hovinga JA, George JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005 3 : 1432 6.
2. Bell W. Thrombotic thrombocytopenic purpura. JAMA 1991 265 : 91 3.
3. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991 325 : 393 7.
4. Tuncer HH, Oster RA, Huang ST, Marques MB. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion 2007 47 : 107 14.
5. Shumak KH, Rock GA, Nair RC. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med 1995 122 : 569 72.
6. Roberts AW, Gillett EA, Fleming SJ. Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange. J Clin Apherisis 1991 6 : 150 54.
7. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998 339 : 1578 84.
8. George JN. The role of ADAMTS13 in the pathogenesis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clin Adv Hematol Oncol 2005 3 : 627 32.
9. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998 339 : 1585 94.
10. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007 109 : 2815 22.
11. Kappers-Klunne MC, Wijermans P, Fijnheer R, Croockewit AJ, van der Holt B, de Wolf JT et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol 2005 130 : 768 76.
12. Ziman A, Mitri M, Klapper E, Pepkowitz SH, Goldfinger D. Combination vincristine and plasma exchange as initial therapy in patients with thrombotic thrombocytopenic purpura: one institution's experience and review of the literature. Transfusion 2005 45 : 41 9.
13. Moake JL, Rudy CK, Troll JH, Schafer AI, Weinstein MJ, Colannino NM et al. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine. Am J Hematol 1985 20 : 73 9.
14. Allan DS, Kovacs MJ, Clark WF. Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 2001 86 : 844 50.
15. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005 106 : 1932 7.
16. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood 2005 106 : 925 8.
17. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol 2004 124 : 787 95.
18. Chow KV, Carroll R, Branley P, Nicholls K, Becker G, Hogan C. Anti-CD20 antibody in thrombotic thrombocytopenic purpura refractory to plasma exchange. Intern Med J 2007 37 : 329 32.
19. George JN. Review of efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura and recurrent thrombotic thrombocytopenic purpura treated repeatedly and successfully with the monoclonal antibody rituximab. Clin Adv Hematol Oncol 2006 4 : 217 18.
20. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apherisis 2006 21 : 49 56.
21. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 350 : 2572 81.